Patient characteristics
| Characteristic . | Randomized patients . | Arm A . | Arm B . |
|---|---|---|---|
| Patients, N | 155 | 76 | 79 |
| Sex ratio, N (M/F) | 80:75 | 38:38 | 42:37 |
| Age, median (IQR), y | 47.1 (38.8-53.8) | 48.8 (38.8-54.0) | 47.0 (39.1-53.5) |
| Aged ≥40 y, N (%) | 113 (72.9) | 55 (72.4) | 58 (73.4) |
| BMI, median (IQR), kg/m2 | 24.9 (22.1-28.4) | 24.9 (22.0-29.1) | 24.7 (22.5-22.8) |
| ECOG PS 0/1/2/3/unknown | 53/73/24/2/3 | 22/39/11/2/2 | 31/34/13/0/1 |
| CNS 3 disease, N (%) | 12 (7.74) | 6 (7.89) | 6 (7.59) |
| WBC, median (IQR), 109/L | 19.4 (6.4-65.2) | 24.3 (7.2-109.0) | 18.0 (6.2-49.0) |
| Karyotype∗ | |||
| Failure, N (yes/no) | 4/151 | 2/74 | 2/77 |
| t(9;22), N (yes/no) | 142/9 | 70/4 | 72/5 |
| ACA, N (yes/no/unknown) | 101/43/11 | 50/21/5 | 51/22/6 |
| Monosomal karyotype, N (yes/no/unknown) | 36/106/11 | 16/55/5 | 22/51/6 |
| bcr subtype, m/M/variant | 107/46/2 | 50/25/1 | 57/21/1 |
| Characteristic . | Randomized patients . | Arm A . | Arm B . |
|---|---|---|---|
| Patients, N | 155 | 76 | 79 |
| Sex ratio, N (M/F) | 80:75 | 38:38 | 42:37 |
| Age, median (IQR), y | 47.1 (38.8-53.8) | 48.8 (38.8-54.0) | 47.0 (39.1-53.5) |
| Aged ≥40 y, N (%) | 113 (72.9) | 55 (72.4) | 58 (73.4) |
| BMI, median (IQR), kg/m2 | 24.9 (22.1-28.4) | 24.9 (22.0-29.1) | 24.7 (22.5-22.8) |
| ECOG PS 0/1/2/3/unknown | 53/73/24/2/3 | 22/39/11/2/2 | 31/34/13/0/1 |
| CNS 3 disease, N (%) | 12 (7.74) | 6 (7.89) | 6 (7.59) |
| WBC, median (IQR), 109/L | 19.4 (6.4-65.2) | 24.3 (7.2-109.0) | 18.0 (6.2-49.0) |
| Karyotype∗ | |||
| Failure, N (yes/no) | 4/151 | 2/74 | 2/77 |
| t(9;22), N (yes/no) | 142/9 | 70/4 | 72/5 |
| ACA, N (yes/no/unknown) | 101/43/11 | 50/21/5 | 51/22/6 |
| Monosomal karyotype, N (yes/no/unknown) | 36/106/11 | 16/55/5 | 22/51/6 |
| bcr subtype, m/M/variant | 107/46/2 | 50/25/1 | 57/21/1 |
ACA, additional chromosomal abnormality; BMI, body mass index; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; PS, performance status; F, female; IQR, interquartile range; M, male; WBC, white blood cell count.
All the 155 patients had bone marrow karyotypes, but 4 karyotypes failed; among the 151 patients with an evaluable karyotype, 142 had the t(9;22) chromosomal translocation; the remaining 9 patients (including 6 normal karyotypes) were BCR::ABL1 fluorescence in situ hybridization positive; among 144 patients, 101 had ACA and 43 did not.